BioSpace News Archive

After months of touting its efficacy to the western world, the efficacy of Russia’s Sputnik V vaccine has been validated in a peer-reviewed study published in The Lancet.

There were two reported cases of trials restarting and one pausing this week. Here’s a look.

Bristol Myers Squibb announced positive data from POETYK PSO-2, the second Phase III trial of deucravacitinib for moderate to severe plaque psoriasis.

Prothena said it anticipates beginning the Phase III study of birtamimab, previously known as NEOD001, in mid-2021.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.

Clene Nanomedicine was awarded a crucial patent from the U.S. Patent and Trademark Office for its patented clean-surfaced gold nanocrystals used for treating patients with multiple sclerosis.

Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases. Here’s a look at three of them.

MOMA Therapeutics and Eli Lilly are both experiencing significant changes in their leadership roster, with one Takeda alum taking the helm at MOMA and an R&D chief at Lilly shooting toward the exit door.

Eagle Pharmaceuticals is still struggling to get its generic vasopressin to market, announcing both a regulatory stall and an additional trial delay for a patent case with Endo Par Innovation Company over the drug.

Medical community struggles over how to help patients with long-lasting, serious side effects even after “recovering” from COVID-19 infection.